(Q37392138)

20 August 2017

1 reference

title

Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions (English)

1 reference

20 August 2017

1 reference

Roland Andersson

1

1 reference

20 August 2017

Ursula Aho

2

1 reference

20 August 2017

Bo I Nilsson

3

1 reference

20 August 2017

Godefridus J Peters

4

1 reference

20 August 2017

Marçal Pastor-Anglada

5

1 reference

20 August 2017

Wenche Rasch

6

1 reference

20 August 2017

Marit L Sandvold

7

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Scandinavian Journal of Gastroenterology

20 August 2017

published in

1 reference

20 August 2017

volume

44

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

782-786

1 reference

20 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Impact of gemcitabine on the treatment of metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Gemcitabine resistance in pancreatic cancer: picking the key players

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Molecular mechanisms of pancreatic cancer and potential targets of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902745039

10.1080/00365520902745039

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference